MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Osmotic demyelination syndrome with dystonia and parkinsonism responsive to dopaminergic therapy

L.E. Katus, S.J. Frucht (New York, NY, USA)

Meeting: 2016 International Congress

Abstract Number: 1769

Keywords: Dopamine agonists, Dystonia: Treatment, Parkinsonism

Session Information

Date: Thursday, June 23, 2016

Session Title: Other

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To present a case of delayed-onset dystonia and parkinsonism secondary to osmotic demyelination syndrome, with dramatic response to pramipexole 3mg per day.

Background: Osmotic demyelination syndrome, otherwise known as pontine myelinolysis, commonly affects extra-pontine areas in the cerebrum (de Souza. Parkinsonism Relat Disord 2013). Striatal involvement often results in movement disorders, which typically have limited response to treatment (de Souza. Parkinsonism Relat Disord 2013).

Methods: We report a 43 year old man with central osmotic demyelination syndrome affecting the pallidum. He developed delayed-onset dystonia and parkinsonism, with significant craniofacial involvement and marked dysarthria and dysphagia. He was followed clinically with serial video documentation, and various pharmacologic treatments were tried including pramipexole.

Results: Despite prior treatment with levodopa 450mg/day, amantadine 200mg/day, and trihexylphenidyl 6mg/day, the patient’s dystonia and parkinsonism did not improve. Pramipexole was started and remarkable improvement was noted at a dose of 3mg per day, particularly in speech. Symptoms worsened when pramipexole was discontinued for severe impulse control disorder. Once his mood was stabilized with lamotrigine, he was restarted on pramipexole with reproducible improvement in speech. Videos at each phase are included.

Conclusions: The explanation for our patient’s particular response to pramipexole at 3mg/day dosing is unclear. Symptom worsening with the discontinuation of pramipexole and the reproducible improvement with its resumption argues against spontaneous fluctuations in the patient’s condition. Levodopa seemed to have no appreciable beneficial affect. It is possible the post-synaptic action of pramipexole accounts for its unique effectiveness in our patient’s case.

To cite this abstract in AMA style:

L.E. Katus, S.J. Frucht. Osmotic demyelination syndrome with dystonia and parkinsonism responsive to dopaminergic therapy [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/osmotic-demyelination-syndrome-with-dystonia-and-parkinsonism-responsive-to-dopaminergic-therapy/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/osmotic-demyelination-syndrome-with-dystonia-and-parkinsonism-responsive-to-dopaminergic-therapy/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley